Overview
Global investment firm focused on medical innovation and societal impact.
Founded
2018
Deals · 12mo
3
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Bionyra Pharma | Jun 2026Led | $165 MSeries A | |
ADCendo | Apr 2026Led | $76 MSeries C | |
Alveus Therapeutics | Mar 2026Participated | $197 MSeries A | |
Odyssey Therapeutics | Sep 2025Participated | $213 MSeries D | |
ReproNovo | May 2025Led | $65 MSeries A | |
Azafaros | May 2025Led | $155 MSeries B | |
Augustine Therapeutics | Mar 2025Led | $91 MSeries A | |
Callio Therapeutics | Mar 2025Participated | $187 MSeries A | |
XyloCor Therapeutics | Jan 2025Led | $68 MSeries B | |
Aviceda Therapeutics | Jan 2025Participated | $208 MSeries C | |
Noema Pharma | Dec 2024Participated | $162 MSeries B | |
Alentis Therapeutics | Nov 2024Led | $181 MSeries D | |
Bionyra Pharma | Jun 2026Led | $165 MSeries A | |
ADCendo | Apr 2026Led | $76 MSeries C | |
Alveus Therapeutics | Mar 2026Participated | $197 MSeries A | |
Odyssey Therapeutics | Sep 2025Participated | $213 MSeries D | |
ReproNovo | May 2025Led | $65 MSeries A | |
Azafaros | May 2025Led | $155 MSeries B | |
Augustine Therapeutics | Mar 2025Led | $91 MSeries A | |
Callio Therapeutics | Mar 2025Participated | $187 MSeries A | |
XyloCor Therapeutics | Jan 2025Led | $68 MSeries B | |
Aviceda Therapeutics | Jan 2025Participated | $208 MSeries C | |
Noema Pharma | Dec 2024Participated | $162 MSeries B | |
Alentis Therapeutics | Nov 2024Led | $181 MSeries D |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 8 | 4 |
| Series B | 6 | 4 |
| Series C+ | 5 | 4 |
| Other Equity | 1 | 2 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Sep '20 | 1 |
| Oct '20 | 1 |
| Nov '20 | 0 |
| Dec '20 | 1 |
| Jan '21 | 0 |
| Feb '21 | 0 |
| Mar '21 | 0 |
| Apr '21 | 0 |
| May '21 | 1 |
| Jun '21 | 1 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 1 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 2 |
| Mar '22 | 1 |
| Apr '22 | 2 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 1 |
| Oct '22 | 0 |
| Nov '22 | 2 |
| Dec '22 | 1 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 1 |
| Apr '23 | 1 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 1 |
| Oct '23 | 0 |
| Nov '23 | 2 |
| Dec '23 | 0 |
| Jan '24 | 1 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 1 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 1 |
| Dec '24 | 1 |
| Jan '25 | 2 |
| Feb '25 | 0 |
| Mar '25 | 2 |
| Apr '25 | 0 |
| May '25 | 2 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 1 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 1 |
| Apr '26 | 1 |
| May '26 | 0 |
| Jun '26 | 1 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 34 |
| Manufacturing | 3 |
| Consumer & Lifestyle | 2 |
| Education & Workforce | 1 |
| Fintech | 1 |
| Social & Community Platforms | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 0 |
| $10M-$25M | 1 |
| $25M-$50M | 1 |
| $50M-$100M | 18 |
| $100M-$250M | 14 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| Europe | 25 |
| United States | 9 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Novo Holdings | 9 |
| Omega Funds | 7 |
| Bpifrance | 6 |
| Forbion | 6 |
| SV Health Investors | 5 |
| Gilde Healthcare | 4 |
| OrbiMed | 4 |
| Pureos Bioventures | 4 |
| RA Capital Management | 4 |
| UPMC Enterprises | 4 |
| Ysios Capital | 4 |
| INKEF Capital | 3 |
| Polaris Partners | 3 |
| Pontifax | 3 |
| Sanofi Ventures | 3 |
| Schroders Capital | 3 |
| Sofinnova Partners | 3 |
| V-Bio Ventures | 3 |
| Vida Ventures | 3 |
| 4BIO Capital | 2 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 20 | 59% |
| Participating | 14 | 41% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 6 | 30% |
| Co-led | 14 | 70% |